OncoFirm -L
Rapid Test Panel for Early Lung Cancer Detection
Overview:
OncoFirm -L is a cutting-edge rapid diagnostic panel developed by OncoFirm Diagnostics, designed to support the early detection of lung cancer in clinical settings. Utilizing lateral flow assay (LFA) technology enhanced with TF and Gal-GalNAc antigens, this test provides fast, accurate, and non-invasive screening—empowering healthcare professionals to identify lung cancer at a stage when treatment is most effective.
Key Features:
- Biomarker-Driven Accuracy: Detects specific glycan antigens (TF and Gal-GalNAc) commonly overexpressed in lung tumor cells.
- Rapid Turnaround: Delivers clear, actionable results in under 15 minutes using blood, plasma, or serum.
- Smart-Ready: Compatible with digital readers and mobile health platforms for enhanced tracking and analysis.
- No Specialized Equipment Needed: Ideal for point-of-care settings, outpatient clinics, and resource-limited environments.
- Cost-Effective Screening: Reduces dependency on expensive imaging for preliminary detection.
Clinical Applications:
- Early detection and screening of non-small cell lung cancer (NSCLC) and related pulmonary tumors
- Use in high-risk patients, including smokers, individuals with a family history of lung cancer, and chronic respiratory patients
- Integration into primary care and oncology referral workflows
- Complement to low-dose CT scans in ongoing surveillance programs
Benefits for Healthcare Providers:
- Enables earlier intervention and improved prognosis
- Simplifies cancer screening in outpatient and decentralized care settings
- Supports fast triage and risk assessment without waiting on lab infrastructure
Regulatory Status:
CE-marked for use in approved international markets. Additional clinical trials are ongoing to support regulatory filings in the United States and other regions.